159 related articles for article (PubMed ID: 30580007)
1. Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer.
Chang EM; Punglia RS; Steinberg ML; Raldow AC
Urology; 2019 Apr; 126():89-95. PubMed ID: 30580007
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment.
Zubek VB; Konski A
Mol Diagn Ther; 2009; 13(1):31-47. PubMed ID: 19351214
[TBL] [Abstract][Full Text] [Related]
3. Cost Effectiveness of the Oncotype DX DCIS Score for Guiding Treatment of Patients With Ductal Carcinoma In Situ.
Raldow AC; Sher D; Chen AB; Recht A; Punglia RS
J Clin Oncol; 2016 Nov; 34(33):3963-3968. PubMed ID: 27621393
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results.
Yun H; Kim J; Gandhe A; Nelson B; Hu JC; Gulani V; Margolis D; Schackman BR; Jalali A
JAMA Netw Open; 2023 Nov; 6(11):e2344856. PubMed ID: 38019516
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer.
Lobo JM; Trifiletti DM; Sturz VN; Dicker AP; Buerki C; Davicioni E; Cooperberg MR; Karnes RJ; Jenkins RB; Den RB; Showalter TN
Clin Genitourin Cancer; 2017 Jun; 15(3):e299-e309. PubMed ID: 28089723
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer.
Roth JA; Ramsey SD; Carlson JJ
Oncologist; 2015 Dec; 20(12):1355-64. PubMed ID: 26482553
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the Cost-Effectiveness of Hydrogel Rectal Spacer in Prostate Cancer Radiation Therapy.
Levy JF; Khairnar R; Louie AV; Showalter TN; Mullins CD; Mishra MV
Pract Radiat Oncol; 2019 Mar; 9(2):e172-e179. PubMed ID: 30342180
[TBL] [Abstract][Full Text] [Related]
8. Comparative Cost-effectiveness of the Baerveldt Implant, Trabeculectomy With Mitomycin, and Medical Treatment.
Kaplan RI; De Moraes CG; Cioffi GA; Al-Aswad LA; Blumberg DM
JAMA Ophthalmol; 2015 May; 133(5):560-7. PubMed ID: 25741886
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
Yang M; Rajan S; Issa AM
Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
[TBL] [Abstract][Full Text] [Related]
11. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
[TBL] [Abstract][Full Text] [Related]
12. Impact and Cost-Effectiveness of Oncotype DX for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer.
El Karak F; Rassy E; Bassil J; Awali M; Hanna C; Saroufim A; Nasr F; Farhat F; Kattan J; Ghosn M; Paulden M
Gulf J Oncolog; 2021 Jan; 1(35):27-35. PubMed ID: 33716210
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Corticosteroid Nasal Spray vs Surgical Therapy in Patients With Severe to Extreme Anatomical Nasal Obstruction.
Teti VP; Akdagli S; Most SP
JAMA Facial Plast Surg; 2016 May; 18(3):165-70. PubMed ID: 26747790
[TBL] [Abstract][Full Text] [Related]
14. The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
DiSantostefano RL; Biddle AK; Lavelle JP
Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases.
Lester-Coll NH; Dosoretz AP; Magnuson WJ; Laurans MS; Chiang VL; Yu JB
J Neurosurg; 2016 Dec; 125(Suppl 1):18-25. PubMed ID: 27903191
[TBL] [Abstract][Full Text] [Related]
16. Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.
Katz G; Romano O; Foa C; Vataire AL; Chantelard JV; Hervé R; Barletta H; Durieux A; Martin JP; Salmon R
PLoS One; 2015; 10(6):e0128880. PubMed ID: 26086912
[TBL] [Abstract][Full Text] [Related]
17. Economic Decision Model for First-Time Traumatic Patellar Dislocations in Adolescents.
Nwachukwu BU; So C; Schairer WW; Shubin Stein BE; Strickland SM; Green DW; Dodwell ER
Am J Sports Med; 2017 Aug; 45(10):2267-2275. PubMed ID: 28463547
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer.
Deshmukh AA; Shirvani SM; Lal L; Swint JM; Cantor SB; Smith BD; Likhacheva A
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059428
[TBL] [Abstract][Full Text] [Related]
19. Analyzing cost-effectiveness of ulnar and median nerve transfers to regain forearm flexion.
Wali AR; Park CC; Brown JM; Mandeville R
Neurosurg Focus; 2017 Mar; 42(3):E11. PubMed ID: 28245686
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
